Paz J. Vellanki

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima et al. · Journal of Clinical Oncology · 2022 · 82 citations

Medicine, Oncology, Pharmacology +13

T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers

Kristen E. Schratz, Diane A. Flasch, Christine C. Atik et al. · Cancer Cell · 2023 · 68 citations · Full text

Medicine, Immunology, Oncology +17

Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes

Aanika Balaji, Jiajia Zhang, Beatriz Wills et al. · Journal of Oncology Practice · 2019 · 61 citations · Full text

Medicine, Oncology, Pharmacology +13

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

Abigail L. Koch, Paz J. Vellanki, Nicole Drezner et al. · Clinical Cancer Research · 2021 · 61 citations · Full text

Medicine, Oncology, Pharmacology +17

FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review

Paz J. Vellanki, Flora Mulkey, Adnan A. Jaigirdar et al. · Clinical Cancer Research · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacology +16